-
Phase 2
-
-
18+Age Range
-
Active, Not Recruiting
Active, Not Recruiting
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC).
Experimental: Part 1: BMS-986315 DL 2 + Nivolumab + Histology-based PDCT
Experimental: Part 1: BMS-986315 Dose Level (DL) 1 + Nivolumab + Histology-based PDCT
Experimental: Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCT
Experimental: Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCT
Active Comparator: Part 2: Nivolumab + Histology-based PDCT